Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis

Thyroid. 1996 Aug;6(4):301-4. doi: 10.1089/thy.1996.6.301.

Abstract

To deliver optimal radioiodine activity in hemodialyzed patients with thyroid carcinoma, the behavior of radioiodine was followed during six treatments. During hemodialysis, blood activity decreases with a half-life of 3.4 +/- 0.5, (1SD) h. The whole body dose was calculated from the total activity determined during 10 days after 131I administration. A reasonable strategy may consist in delivering 25% of the currently prescribed activity (925 MBq-25 mCi) and to perform the first dialysis session after 24 h to reduce total body irradiation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Carcinoma, Papillary / complications*
  • Carcinoma, Papillary / radiotherapy*
  • Fatal Outcome
  • Female
  • Graft Rejection / physiopathology
  • Humans
  • Hypertension, Renovascular / complications
  • Iodine Radioisotopes / blood
  • Iodine Radioisotopes / therapeutic use
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / therapy
  • Kidney Transplantation / physiology
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Metastasis
  • Pancreas Transplantation / physiology
  • Radiation Dosage
  • Renal Dialysis*
  • Thyroid Neoplasms / complications*
  • Thyroid Neoplasms / radiotherapy*
  • Thyroidectomy
  • Whole-Body Counting

Substances

  • Iodine Radioisotopes